Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors

S. Forrest Dodson, C. Andrew Bonham, David A. Geller, Thomas V. Cacciarelli, Jorge Rakela, John J. Fung

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Background. The shortage of donor organs occasionally mandates the use of hepatic allografts from anti-HBc+ donors in recipients who are susceptible to de novo hepatitis B virus (HBV) infection. The efficacy of hepatitis B immune globulin and lamivudine to prevent de novo HBV infection in anti-HBs negative recipients of allografts from anti-HBc+ donors has not been investigated. Methods. After liver transplantation with an allograft from a donor positive for anti-HBc, recipients who were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days and monthly for 6 months. After 6 months, 1000 IU of HBIG was given IM. every 2 weeks for 18 months. Patients transplanted after 4/1/97 were given lamivudine 150 mg daily starting postoperative day 1. Results. Between 8/14/96 and 6/10/98, 264 orthotopic liver transplants were performed and 16 anti-HBs-, HbsAg- patients received an hepatic allograft from a donor positive for anti-HBc. HBIG mono-therapy was administered to one patient. HBIG and lamivudine combination therapy was administered to 15 patients. Of the 16 patients, 8 were positive only for anti-HBc before transplant, and 8 were naive (anti-HBs-, anti-HBc-). The single patient who received HBIG monotherapy became HbsAg+ at 6 months. All patients receiving combination therapy with HBIG and lamivudine have remained HbsAg-. The average follow-up is 459 days (range 170-754). Two patients died from unrelated causes. Conclusions. Combination therapy with HBIG and lamivudine may prevent de novo HBV infection in anti-HBs-, HbsAg- recipients of hepatic allografts from anti-HBc+ donors.

Original languageEnglish (US)
Pages (from-to)1058-1061
Number of pages4
JournalTransplantation
Volume68
Issue number7
DOIs
StatePublished - Oct 15 1999
Externally publishedYes

Fingerprint

Hepatitis B
Allografts
Immunoglobulins
Lamivudine
Tissue Donors
Liver
Infection
Virus Diseases
Hepatitis B virus
Transplants
Therapeutics
Liver Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. / Dodson, S. Forrest; Bonham, C. Andrew; Geller, David A.; Cacciarelli, Thomas V.; Rakela, Jorge; Fung, John J.

In: Transplantation, Vol. 68, No. 7, 15.10.1999, p. 1058-1061.

Research output: Contribution to journalArticle

Dodson, S. Forrest ; Bonham, C. Andrew ; Geller, David A. ; Cacciarelli, Thomas V. ; Rakela, Jorge ; Fung, John J. / Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. In: Transplantation. 1999 ; Vol. 68, No. 7. pp. 1058-1061.
@article{5402453190d64fbc960aea5ab5b1b793,
title = "Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors",
abstract = "Background. The shortage of donor organs occasionally mandates the use of hepatic allografts from anti-HBc+ donors in recipients who are susceptible to de novo hepatitis B virus (HBV) infection. The efficacy of hepatitis B immune globulin and lamivudine to prevent de novo HBV infection in anti-HBs negative recipients of allografts from anti-HBc+ donors has not been investigated. Methods. After liver transplantation with an allograft from a donor positive for anti-HBc, recipients who were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days and monthly for 6 months. After 6 months, 1000 IU of HBIG was given IM. every 2 weeks for 18 months. Patients transplanted after 4/1/97 were given lamivudine 150 mg daily starting postoperative day 1. Results. Between 8/14/96 and 6/10/98, 264 orthotopic liver transplants were performed and 16 anti-HBs-, HbsAg- patients received an hepatic allograft from a donor positive for anti-HBc. HBIG mono-therapy was administered to one patient. HBIG and lamivudine combination therapy was administered to 15 patients. Of the 16 patients, 8 were positive only for anti-HBc before transplant, and 8 were naive (anti-HBs-, anti-HBc-). The single patient who received HBIG monotherapy became HbsAg+ at 6 months. All patients receiving combination therapy with HBIG and lamivudine have remained HbsAg-. The average follow-up is 459 days (range 170-754). Two patients died from unrelated causes. Conclusions. Combination therapy with HBIG and lamivudine may prevent de novo HBV infection in anti-HBs-, HbsAg- recipients of hepatic allografts from anti-HBc+ donors.",
author = "Dodson, {S. Forrest} and Bonham, {C. Andrew} and Geller, {David A.} and Cacciarelli, {Thomas V.} and Jorge Rakela and Fung, {John J.}",
year = "1999",
month = "10",
day = "15",
doi = "10.1097/00007890-199910150-00028",
language = "English (US)",
volume = "68",
pages = "1058--1061",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors

AU - Dodson, S. Forrest

AU - Bonham, C. Andrew

AU - Geller, David A.

AU - Cacciarelli, Thomas V.

AU - Rakela, Jorge

AU - Fung, John J.

PY - 1999/10/15

Y1 - 1999/10/15

N2 - Background. The shortage of donor organs occasionally mandates the use of hepatic allografts from anti-HBc+ donors in recipients who are susceptible to de novo hepatitis B virus (HBV) infection. The efficacy of hepatitis B immune globulin and lamivudine to prevent de novo HBV infection in anti-HBs negative recipients of allografts from anti-HBc+ donors has not been investigated. Methods. After liver transplantation with an allograft from a donor positive for anti-HBc, recipients who were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days and monthly for 6 months. After 6 months, 1000 IU of HBIG was given IM. every 2 weeks for 18 months. Patients transplanted after 4/1/97 were given lamivudine 150 mg daily starting postoperative day 1. Results. Between 8/14/96 and 6/10/98, 264 orthotopic liver transplants were performed and 16 anti-HBs-, HbsAg- patients received an hepatic allograft from a donor positive for anti-HBc. HBIG mono-therapy was administered to one patient. HBIG and lamivudine combination therapy was administered to 15 patients. Of the 16 patients, 8 were positive only for anti-HBc before transplant, and 8 were naive (anti-HBs-, anti-HBc-). The single patient who received HBIG monotherapy became HbsAg+ at 6 months. All patients receiving combination therapy with HBIG and lamivudine have remained HbsAg-. The average follow-up is 459 days (range 170-754). Two patients died from unrelated causes. Conclusions. Combination therapy with HBIG and lamivudine may prevent de novo HBV infection in anti-HBs-, HbsAg- recipients of hepatic allografts from anti-HBc+ donors.

AB - Background. The shortage of donor organs occasionally mandates the use of hepatic allografts from anti-HBc+ donors in recipients who are susceptible to de novo hepatitis B virus (HBV) infection. The efficacy of hepatitis B immune globulin and lamivudine to prevent de novo HBV infection in anti-HBs negative recipients of allografts from anti-HBc+ donors has not been investigated. Methods. After liver transplantation with an allograft from a donor positive for anti-HBc, recipients who were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days and monthly for 6 months. After 6 months, 1000 IU of HBIG was given IM. every 2 weeks for 18 months. Patients transplanted after 4/1/97 were given lamivudine 150 mg daily starting postoperative day 1. Results. Between 8/14/96 and 6/10/98, 264 orthotopic liver transplants were performed and 16 anti-HBs-, HbsAg- patients received an hepatic allograft from a donor positive for anti-HBc. HBIG mono-therapy was administered to one patient. HBIG and lamivudine combination therapy was administered to 15 patients. Of the 16 patients, 8 were positive only for anti-HBc before transplant, and 8 were naive (anti-HBs-, anti-HBc-). The single patient who received HBIG monotherapy became HbsAg+ at 6 months. All patients receiving combination therapy with HBIG and lamivudine have remained HbsAg-. The average follow-up is 459 days (range 170-754). Two patients died from unrelated causes. Conclusions. Combination therapy with HBIG and lamivudine may prevent de novo HBV infection in anti-HBs-, HbsAg- recipients of hepatic allografts from anti-HBc+ donors.

UR - http://www.scopus.com/inward/record.url?scp=0033569838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033569838&partnerID=8YFLogxK

U2 - 10.1097/00007890-199910150-00028

DO - 10.1097/00007890-199910150-00028

M3 - Article

C2 - 10532552

AN - SCOPUS:0033569838

VL - 68

SP - 1058

EP - 1061

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 7

ER -